Cardiol Therapeutics Inc. announced that its President and CEO will participate in a live interview on April 14, 2026, to discuss the ongoing Phase III MAVERIC trial for recurrent pericarditis, published Phase II ARCHER results for acute myocarditis, and the development of next-generation drug CRD-38 for heart failure.
Key takeaways
CEO David Elsley will conduct a live interview on X with Barchart on April 14, 2026, at 12:00 PM EDT to discuss company developments.
The interview will cover the ongoing pivotal Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis, an inflammatory heart disease.
Discussion will include results from the recently published Phase II ARCHER trial of CardiolRx™ in acute myocarditis, a cause of heart failure in young adults.
The company will also discuss CRD-38, a novel subcutaneous drug formulation in development for inflammatory heart disease including heart failure.
CardiolRx™ has received U.S. FDA Orphan Drug Designation for the treatment of pericarditis, including recurrent pericarditis.
The MAVERIC program includes a completed Phase II study and ongoing Phase III trial, while the ARCHER program includes a completed Phase II study.